Abnormal expression of circulating and tumor-infiltrating carcinoembryonic antigen-related cell adhesion molecule 1 in patients with glioma

Li,Jinhu; Liu,Xiaodong; Duan,Yijun; Wang,Hongqin; Su,Wen; Wang,Yazhou; Zhuang,Guotao; Fan,Yimin

doi:10.3892/ol.2018.7786

Abnormal expression of circulating and tumor-infiltrating carcinoembryonic antigen-related cell adhesion molecule 1 in patients with glioma

Authors:
- Jinhu Li
- Xiaodong Liu
- Yijun Duan
- Hongqin Wang
- Wen Su
- Yazhou Wang
- Guotao Zhuang
- Yimin Fan
View Affiliations

Affiliations: Department of Neurosurgery, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China, Department of Immunology, Shanxi Provincial Cancer Hospital, Taiyuan, Shanxi 030013, P.R. China, Department of Neurosurgery, People's Hospital of Zhengzhou, Zhengzhou, Henan 450053, P.R. China, Department of Neurosurgery, The Fifth People's Hospital of Datong, Datong, Shanxi 037006, P.R. China
Published online on: January 12, 2018 https://doi.org/10.3892/ol.2018.7786
Pages: 3496-3503
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioma, the most prevalent primary tumor of the central nervous system, is known to evade immune surveillance and escape immune attacks by inducing immunosuppression. The homophilic interactions of the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) serve a critical function in immunoregulation. In the present study, the expression levels of CEACAM1 in peripheral blood mononuclear cells and tumor‑infiltrating lymphocytes (TILs) from patients with gliomas were assessed. Furthermore, associations between CEACAM1 expression and multiple clinicopathological characteristics in patients with gliomas were analyzed. The results of the present study suggested that the expression of CEACAM1 in circulating T cells was markedly increased in patients with gliomas compared with control subjects, and was further increased in TILs. Patients with high‑grade gliomas [World Health Organization (WHO) grade III‑IV] demonstrated a significantly increased expression of CEACAM1 on T cells compared with those with low‑grade gliomas (WHO grade I‑II). Furthermore, the expression of CEACAM1 on T cells was negatively correlated with the Karnofsky score and the plasma level of interferon‑γ in patients with gliomas. Immunohistochemical analysis revealed that the expression levels of CEACAM1 in high‑grade glioma tissues (WHO grade III‑IV) were increased compared with the expression levels in the controls, and were associated with the expression of CEACAM1 in TILs. In summary, the results of the present study indicate that homophilic interactions of CEACAM1 may participate in the progression and development of gliomas through their negative regulatory effects on T cells. Thus, CEACAM1 may be a promising candidate for targeted glioma immunotherapy.

View Figures

View References

1	Porter KR, Mccarthy BJ, Freels S, Kim Y and Davis FG: Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro-Oncology. 12:520–527. 2010. View Article : Google Scholar : PubMed/NCBI
2	Pan J, Zhao X, Lin C, Xu H, Yin Z, Liu T and Zhang S: Immune responsive gene 1, a novel oncogene, increases the growth and tumorigenicity of glioma. Oncol Rep. 32:1957–1966. 2014. View Article : Google Scholar : PubMed/NCBI
3	Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
4	Wang N, Feng Y, Wang Q, Liu S, Xiang L, Sun M, Zhang X, Liu G, Qu X and Wei F: Neutrophils infiltration in the tongue squamous cell carcinoma and its correlation with CEACAM1 expression on tumor cells. PLoS One. 9:e899912014. View Article : Google Scholar : PubMed/NCBI
5	Kiriyama S, Yokoyama S, Ueno M, Hayami S, Ieda J, Yamamoto N, Yamaguchi S, Mitani Y, Nakamura Y, Tani M, et al: CEACAM1 long cytoplasmic domain isoform is associated with invasion and recurrence of hepatocellular carcinoma. Ann Surg Oncol. 21 Suppl 4:S505–S514. 2014. View Article : Google Scholar : PubMed/NCBI
6	Dupuis ML, Fiori V, Soriani A, Ricci B, Dominici S, Moricoli D, Ascione A, Santoni A, Magnani M and Cianfriglia M: The human antibody fragment DIATHIS1 specific for CEACAM1 enhances natural killer cell cytotoxicity against melanoma cell lines in vitro. J Immunother. 38:357–370. 2015. View Article : Google Scholar : PubMed/NCBI
7	Markel G, Sapir Y, Mandel I, Hakim M, Shaked R, Meilin E, McClanahan T, Loboda A, Hashmueli S and Ben Moshe T: Inhibition of the novel immune checkpoint CEACAM1 to enhance anti-tumor immunological activity. J Clin Oncol. 34:2016.
8	Markel G, Seidman R, Stern N, Cohen-Sinai T, Izhaki O, Katz G, Besser M, Treves AJ, Blumberg RS, Loewenthal R, et al: Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions. J Immunol. 177:6062–6071. 2006. View Article : Google Scholar : PubMed/NCBI
9	Markel G, Lieberman N, Katz G, Arnon TI, Lotem M, Drize O, Blumberg RS, Bar-Haim E, Mader R, Eisenbach L and Mandelboim O: CD66a interactions between human melanoma and NK cells: A novel class I MHC-independent inhibitory mechanism of cytotoxicity. J Immunol. 168:2803–2810. 2002. View Article : Google Scholar : PubMed/NCBI
10	Hosomi S, Chen Z, Baker K, Chen L, Huang YH, Olszak T, Zeissig S, Wang JH, Mandelboim O, Beauchemin N, et al: CEACAM1 on activated NK cells inhibits NKG2D-mediated cytolytic function and signaling. Eur J Immunol. 43:2473–2483. 2013. View Article : Google Scholar : PubMed/NCBI
11	Chen Z, Chen L, Baker K, Olszak T, Zeissig S, Huang YH, Kuo TT, Mandelboim O, Beauchemin N, Lanier LL and Blumberg RS: CEACAM1 dampens antitumor immunity by down-regulating NKG2D ligand expression on tumor cells. J Exp Med. 208:2633–2640. 2011. View Article : Google Scholar : PubMed/NCBI
12	Ortenberg R, Sapir Y, Raz L, Hershkovitz L, Ben Arav A, Sapoznik S, Barshack I, Avivi C, Berkun Y, Besser MJ, et al: Novel immunotherapy for malignant melanoma with a monoclonal antibody that blocks CEACAM1 homophilic interactions. Mol Cancer Ther. 11:1300–1310. 2012. View Article : Google Scholar : PubMed/NCBI
13	Zhang L, Wang J, Wei F, Wang K, Sun Q, Yang F, Jin H, Zheng Y, Zhao H, Wang L, et al: Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients. Oncotarget. 7:43604–43615. 2016.PubMed/NCBI
14	Li Y and Shively JE: CEACAM1 regulates Fas-mediated apoptosis in Jurkat T-cells via its interaction with β-catenin. Exp Cell Res. 319:1061–1072. 2013. View Article : Google Scholar : PubMed/NCBI
15	Grayowen SD and Blumberg RS: CEACAM1: Contact-dependent control of immunity. Nat Rev Immunol. 6:433–446. 2006. View Article : Google Scholar : PubMed/NCBI
16	Ashkenazi S, Ortenberg R, Besser M, Schachter J and Markel G: SOX9 indirectly regulates CEACAM1 expression and immune resistance in melanoma cells. Oncotarget. 7:30166–30177. 2016. View Article : Google Scholar : PubMed/NCBI
17	Zhou Z, Luther N, Ibrahim GM, Hawkins C, Vibhakar R, Handler MH and Souweidane MM: B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma. J Neurooncol. 111:257–264. 2013. View Article : Google Scholar : PubMed/NCBI
18	Lemke D, Pfenning PN, Sahm F, Klein AC, Kempf T, Warnken U, Schnölzer M, Tudoran R, Weller M, Platten M and Wick W: Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness. Clin Cancer Res. 18:105–117. 2012. View Article : Google Scholar : PubMed/NCBI
19	Liu Z, Han H, He X, Li S, Wu C, Yu C and Wang S: Expression of the galectin-9-Tim-3 pathway in glioma tissues is associated with the clinical manifestations of glioma. Oncol Lett. 11:1829–1834. 2016. View Article : Google Scholar : PubMed/NCBI
20	Wainwright DA, Chang AL, Dey M, Balyasnikova IV, Kim CK, Tobias A, Cheng Y, Kim JW, Qiao J, Zhang L, et al: Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4 and PD-L1 in mice with brain tumors. Clin Cancer Res. 20:5290–5301. 2014. View Article : Google Scholar : PubMed/NCBI
21	Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
22	Johnson MJ, Bland JM, Davidson PM, Newton PJ, Oxberry SG, Abernethy AP and Currow DC: The relationship between two performance scales: New York heart association classification and karnofsky performance status scale. J Pain Symptom Manage. 47:652–658. 2014. View Article : Google Scholar : PubMed/NCBI
23	Feng F, Kuai D, Wang H, Li T, Miao W, Liu Y and Fan Y: Reduced expression of microRNA-497 is associated with greater angiogenesis and poor prognosis in human gliomas. Hum Pathol. 58:47–53. 2016. View Article : Google Scholar : PubMed/NCBI
24	Hong B, Li H, Lu Y, Zhang M, Zheng Y, Qian J and Yi Q: USP18 is crucial for IFN-γ-mediated inhibition of B16 melanoma tumorigenesis and antitumor immunity. Mol Cancer. 13:1322014. View Article : Google Scholar : PubMed/NCBI
25	Platten M, Weller M and Wick W: Shaping the glioma immune microenvironment through tryptophan metabolism. CNS Oncol. 1:99–106. 2012. View Article : Google Scholar : PubMed/NCBI
26	Sharma P and Allison JP: The future of immune checkpoint therapy. Science. 348:56–61. 2015. View Article : Google Scholar : PubMed/NCBI
27	Kim ES, Kim JE, Patel MA, Mangraviti A, Ruzevick J and Lim M: Immune checkpoint modulators: An emerging antiglioma armamentarium. J Immunol Res. 2016:46836072016. View Article : Google Scholar : PubMed/NCBI
28	Ahn BJ, Pollack IF and Okada H: Immune-Checkpoint blockade and active immunotherapy for glioma. Cancers. 5:1379–1412. 2013. View Article : Google Scholar : PubMed/NCBI
29	Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, Yagita H, Overwijk WW, Lizée G, Radvanyi L and Hwu P: PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. Cancer Res. 72:5209–5218. 2012. View Article : Google Scholar : PubMed/NCBI
30	Han S, Feng S, Xu L, Shi W, Wang X, Wang H, Yu C, Dong T, Xu M and Liang G: Tim-3 on peripheral CD4⁺ and CD8⁺ T cells is involved in the development of glioma. DNA Cell Biol. 33:245–250. 2014. View Article : Google Scholar : PubMed/NCBI
31	Huang YH, Zhu C, Kondo Y, Anderson AC, Gandhi A, Russell A, Dougan SK, Petersen BS, Melum E, Pertel T, et al: CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature. 517:386–390. 2015. View Article : Google Scholar : PubMed/NCBI